Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

INTRODUCTION: We report the impact of canakinumab, a fully human anti-interleukin-1β monoclonal antibody, on inflammation and health-related quality of life (HRQoL) in patients with difficult-to-treat Gouty Arthritis. METHODS: In this eight-week, single-blind, double-dummy, dose-ranging study, patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlesinger, Naomi, De Meulemeester, Marc, Pikhlak, Andrey, Yücel, A Eftal, Richard, Dominik, Murphy, Valda, Arulmani, Udayasankar, Sallstig, Peter, So, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132043/
https://www.ncbi.nlm.nih.gov/pubmed/21439048
http://dx.doi.org/10.1186/ar3297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132043/
https://www.ncbi.nlm.nih.gov/pubmed/21439048
http://dx.doi.org/10.1186/ar3297

Ejemplares similares